Dr. Alex Fichtenholtz is an industry-leading expert in the fields of cancer genomics analysis and development of next-generation sequencing processing pipelines. Having joined Foundation Medicine, Inc. (later acquired by Roche) and Resolution Bioscience (later acquired by Agilent) as an early employee, Dr. Fichtenholtz is seasoned in producing molecular diagnostic technology for both solid tissue and liquid biopsy applications. Besides the direct clinical application of such technologies to late-stage cancer patients, Dr. Fichtenholtz is also passionate about downstream applications of genomic, transcriptomic, and proteomic data. 

Specifically, Dr. Fichtenholtz is interested in combining these data types with patient-level clinical data to improve the drug discovery and approval process, increase hospital efficiency, and improve payer reimbursement of molecular diagnostic use in clinical settings. When not pursuing professional interests, Dr. Fichtenholtz enjoys soccer, snowboarding, and playing with his dog, Buddy.